Answers are grounded in this paper and cite their sources.
Tolerated and toxic doses of intrathecal and/or intraventricular cytosine arabinoside were studied in dogs and monkeys. Safe dose levels which produce no detectable side effects were established. Intrathecal administration of cytosine arabinoside to nine patients with acute leukemia with central nervous system involvement and to one patient with meningeal involvement secondary to lymphocytic lymphosarcoma resulted in prompt improvement of the clinical findings and regression of laboratory evidence of CNS leukemia. Toxicity consisted of headaches, vomiting and meningismus, perhaps attributable to unbuffered diluent. No hematologic toxicity was observed. Intrathecal Ara-C was active in patients whose CNS disease had escaped from control by intrathecal methotrexate and irradiation. Intrathecal cytosine arabinoside represents an effective agent in the therapy of central nervous system leukemia and lymphosarcoma.
No takes yet. Share an insight, caveat, or question.
Band et al. (1973) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: